Response of T Lymphocyte Populations in Prostate Cancer Patients Undergoing Radiotherapy: Influence of Neoajuvant Total Androgen Suppression
Background: This study sought to better define the immunological impact of combining neoadjuvant total androgen suppression (TAS) with radiotherapy (xRT) in treating prostate cancer. Materials and Methods: Subjects selected (n=37) were stage I-II prostate cancer patients meeting the eligibility requ...
Gespeichert in:
| Veröffentlicht in: | Anticancer research 2005-07, Vol.25 (4), p.3159-3166 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3166 |
|---|---|
| container_issue | 4 |
| container_start_page | 3159 |
| container_title | Anticancer research |
| container_volume | 25 |
| creator | JOHNKE, Roberta M EDWARDS, Judy M O'BRIEN, Kevin F KOVACS, Charles J EVANS, Mark J DALY, Barbara M KARLSSON, Ulf L LEE, Tung-Kwang ALLISON, Ron R ARASTU, Hyder H CARIVEAU, Mickael J |
| description | Background: This study sought to better define the immunological impact of combining neoadjuvant total androgen suppression
(TAS) with radiotherapy (xRT) in treating prostate cancer. Materials and Methods: Subjects selected (n=37) were stage I-II
prostate cancer patients meeting the eligibility requirements for RTOG protocols 94-08 or 94-13. Flow cytometric monitoring
of circulating T helper (T h ), T suppressor/cytotoxic (T s ), natural killer (NK) and B lymphocytes was performed weekly. Results: Significant reduction of all lymphocyte subsets occurred
as a result of xRT. Comparison between treatment groups demonstrated that the B lymphocyte and NK lymphocyte radioresponse
was not influenced by TAS, but the T h and T s lymphocyte response was, with addition of TAS leading to less radiation-induced decline. Conclusion: The basis for this T
cell response is unclear, but may involve a TAS-induced reduction of testosterone's immunomodulation of T cell proliferation
and apoptosis and/or a direct, TAS-induced thymic stimulation. Our data suggest that addition of TAS to xRT appears to have
no detrimental effects on lymphocyte subsets, and, indeed, may have favorable effects on T cells. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_68450459</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68450459</sourcerecordid><originalsourceid>FETCH-LOGICAL-h269t-969e51c27836590416cd6454ca074bc5278a7eb722726b6e9a67af7c47eb82273</originalsourceid><addsrcrecordid>eNpNkMFq3DAYhE1JabZpX6HoktwMsmxJVm5hSdrA0i7p5mz-lX-vFWTJkeSGfYc-dFWyoT0NzHzMwLwrVpVUVSl5Tc-KFWWclpJSfl58jPGJUiFUW38ozitBW8pbuip-P2CcvYtI_EB2ZHOc5tHrY0Ky9fNiIZkcEuPINviYIPtrcBoD2eYIXYrk0fUYDt64A3mA3vg0YoD5eE3u3WAXzPDf6u_o4Wn5BS6RnU9gyY3rgz-gIz-XeQ4YYx76VLwfwEb8fNKL4vHudrf-Vm5-fL1f32zKkQmVSiUU8koz2daCK9pUQvei4Y0GKpu95jkAiXvJmGRiL1CBkDBI3WSzzWZ9UVy99s7BPy8YUzeZqNFacOiX2Im24bThKoNfTuCyn7Dv5mAmCMfu7b8MXJ4AiBrsEPI5Jv7HKSlqxv5xozmMLyZgFyewNtfWHQTGu6arqzz4Bx1RiL4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68450459</pqid></control><display><type>article</type><title>Response of T Lymphocyte Populations in Prostate Cancer Patients Undergoing Radiotherapy: Influence of Neoajuvant Total Androgen Suppression</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>JOHNKE, Roberta M ; EDWARDS, Judy M ; O'BRIEN, Kevin F ; KOVACS, Charles J ; EVANS, Mark J ; DALY, Barbara M ; KARLSSON, Ulf L ; LEE, Tung-Kwang ; ALLISON, Ron R ; ARASTU, Hyder H ; CARIVEAU, Mickael J</creator><creatorcontrib>JOHNKE, Roberta M ; EDWARDS, Judy M ; O'BRIEN, Kevin F ; KOVACS, Charles J ; EVANS, Mark J ; DALY, Barbara M ; KARLSSON, Ulf L ; LEE, Tung-Kwang ; ALLISON, Ron R ; ARASTU, Hyder H ; CARIVEAU, Mickael J</creatorcontrib><description>Background: This study sought to better define the immunological impact of combining neoadjuvant total androgen suppression
(TAS) with radiotherapy (xRT) in treating prostate cancer. Materials and Methods: Subjects selected (n=37) were stage I-II
prostate cancer patients meeting the eligibility requirements for RTOG protocols 94-08 or 94-13. Flow cytometric monitoring
of circulating T helper (T h ), T suppressor/cytotoxic (T s ), natural killer (NK) and B lymphocytes was performed weekly. Results: Significant reduction of all lymphocyte subsets occurred
as a result of xRT. Comparison between treatment groups demonstrated that the B lymphocyte and NK lymphocyte radioresponse
was not influenced by TAS, but the T h and T s lymphocyte response was, with addition of TAS leading to less radiation-induced decline. Conclusion: The basis for this T
cell response is unclear, but may involve a TAS-induced reduction of testosterone's immunomodulation of T cell proliferation
and apoptosis and/or a direct, TAS-induced thymic stimulation. Our data suggest that addition of TAS to xRT appears to have
no detrimental effects on lymphocyte subsets, and, indeed, may have favorable effects on T cells.</description><identifier>ISSN: 0250-7005</identifier><identifier>EISSN: 1791-7530</identifier><identifier>PMID: 16080580</identifier><language>eng</language><publisher>Attiki: International Institute of Anticancer Research</publisher><subject>Aged ; Androgen Antagonists - administration & dosage ; Antineoplastic Agents, Hormonal - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Flutamide - administration & dosage ; Goserelin - administration & dosage ; Humans ; Lymphocyte Activation ; Male ; Medical sciences ; Middle Aged ; Neoadjuvant Therapy ; Neoplasm Staging ; Nephrology. Urinary tract diseases ; Prostatic Neoplasms - drug therapy ; Prostatic Neoplasms - immunology ; Prostatic Neoplasms - radiotherapy ; Prostatic Neoplasms - therapy ; T-Lymphocytes - drug effects ; T-Lymphocytes - immunology ; T-Lymphocytes - radiation effects ; Tumors ; Tumors of the urinary system ; Urinary tract. Prostate gland</subject><ispartof>Anticancer research, 2005-07, Vol.25 (4), p.3159-3166</ispartof><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16976322$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16080580$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>JOHNKE, Roberta M</creatorcontrib><creatorcontrib>EDWARDS, Judy M</creatorcontrib><creatorcontrib>O'BRIEN, Kevin F</creatorcontrib><creatorcontrib>KOVACS, Charles J</creatorcontrib><creatorcontrib>EVANS, Mark J</creatorcontrib><creatorcontrib>DALY, Barbara M</creatorcontrib><creatorcontrib>KARLSSON, Ulf L</creatorcontrib><creatorcontrib>LEE, Tung-Kwang</creatorcontrib><creatorcontrib>ALLISON, Ron R</creatorcontrib><creatorcontrib>ARASTU, Hyder H</creatorcontrib><creatorcontrib>CARIVEAU, Mickael J</creatorcontrib><title>Response of T Lymphocyte Populations in Prostate Cancer Patients Undergoing Radiotherapy: Influence of Neoajuvant Total Androgen Suppression</title><title>Anticancer research</title><addtitle>Anticancer Res</addtitle><description>Background: This study sought to better define the immunological impact of combining neoadjuvant total androgen suppression
(TAS) with radiotherapy (xRT) in treating prostate cancer. Materials and Methods: Subjects selected (n=37) were stage I-II
prostate cancer patients meeting the eligibility requirements for RTOG protocols 94-08 or 94-13. Flow cytometric monitoring
of circulating T helper (T h ), T suppressor/cytotoxic (T s ), natural killer (NK) and B lymphocytes was performed weekly. Results: Significant reduction of all lymphocyte subsets occurred
as a result of xRT. Comparison between treatment groups demonstrated that the B lymphocyte and NK lymphocyte radioresponse
was not influenced by TAS, but the T h and T s lymphocyte response was, with addition of TAS leading to less radiation-induced decline. Conclusion: The basis for this T
cell response is unclear, but may involve a TAS-induced reduction of testosterone's immunomodulation of T cell proliferation
and apoptosis and/or a direct, TAS-induced thymic stimulation. Our data suggest that addition of TAS to xRT appears to have
no detrimental effects on lymphocyte subsets, and, indeed, may have favorable effects on T cells.</description><subject>Aged</subject><subject>Androgen Antagonists - administration & dosage</subject><subject>Antineoplastic Agents, Hormonal - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Flutamide - administration & dosage</subject><subject>Goserelin - administration & dosage</subject><subject>Humans</subject><subject>Lymphocyte Activation</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neoadjuvant Therapy</subject><subject>Neoplasm Staging</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Prostatic Neoplasms - drug therapy</subject><subject>Prostatic Neoplasms - immunology</subject><subject>Prostatic Neoplasms - radiotherapy</subject><subject>Prostatic Neoplasms - therapy</subject><subject>T-Lymphocytes - drug effects</subject><subject>T-Lymphocytes - immunology</subject><subject>T-Lymphocytes - radiation effects</subject><subject>Tumors</subject><subject>Tumors of the urinary system</subject><subject>Urinary tract. Prostate gland</subject><issn>0250-7005</issn><issn>1791-7530</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkMFq3DAYhE1JabZpX6HoktwMsmxJVm5hSdrA0i7p5mz-lX-vFWTJkeSGfYc-dFWyoT0NzHzMwLwrVpVUVSl5Tc-KFWWclpJSfl58jPGJUiFUW38ozitBW8pbuip-P2CcvYtI_EB2ZHOc5tHrY0Ky9fNiIZkcEuPINviYIPtrcBoD2eYIXYrk0fUYDt64A3mA3vg0YoD5eE3u3WAXzPDf6u_o4Wn5BS6RnU9gyY3rgz-gIz-XeQ4YYx76VLwfwEb8fNKL4vHudrf-Vm5-fL1f32zKkQmVSiUU8koz2daCK9pUQvei4Y0GKpu95jkAiXvJmGRiL1CBkDBI3WSzzWZ9UVy99s7BPy8YUzeZqNFacOiX2Im24bThKoNfTuCyn7Dv5mAmCMfu7b8MXJ4AiBrsEPI5Jv7HKSlqxv5xozmMLyZgFyewNtfWHQTGu6arqzz4Bx1RiL4</recordid><startdate>20050701</startdate><enddate>20050701</enddate><creator>JOHNKE, Roberta M</creator><creator>EDWARDS, Judy M</creator><creator>O'BRIEN, Kevin F</creator><creator>KOVACS, Charles J</creator><creator>EVANS, Mark J</creator><creator>DALY, Barbara M</creator><creator>KARLSSON, Ulf L</creator><creator>LEE, Tung-Kwang</creator><creator>ALLISON, Ron R</creator><creator>ARASTU, Hyder H</creator><creator>CARIVEAU, Mickael J</creator><general>International Institute of Anticancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20050701</creationdate><title>Response of T Lymphocyte Populations in Prostate Cancer Patients Undergoing Radiotherapy: Influence of Neoajuvant Total Androgen Suppression</title><author>JOHNKE, Roberta M ; EDWARDS, Judy M ; O'BRIEN, Kevin F ; KOVACS, Charles J ; EVANS, Mark J ; DALY, Barbara M ; KARLSSON, Ulf L ; LEE, Tung-Kwang ; ALLISON, Ron R ; ARASTU, Hyder H ; CARIVEAU, Mickael J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h269t-969e51c27836590416cd6454ca074bc5278a7eb722726b6e9a67af7c47eb82273</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Aged</topic><topic>Androgen Antagonists - administration & dosage</topic><topic>Antineoplastic Agents, Hormonal - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Flutamide - administration & dosage</topic><topic>Goserelin - administration & dosage</topic><topic>Humans</topic><topic>Lymphocyte Activation</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neoadjuvant Therapy</topic><topic>Neoplasm Staging</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Prostatic Neoplasms - drug therapy</topic><topic>Prostatic Neoplasms - immunology</topic><topic>Prostatic Neoplasms - radiotherapy</topic><topic>Prostatic Neoplasms - therapy</topic><topic>T-Lymphocytes - drug effects</topic><topic>T-Lymphocytes - immunology</topic><topic>T-Lymphocytes - radiation effects</topic><topic>Tumors</topic><topic>Tumors of the urinary system</topic><topic>Urinary tract. Prostate gland</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>JOHNKE, Roberta M</creatorcontrib><creatorcontrib>EDWARDS, Judy M</creatorcontrib><creatorcontrib>O'BRIEN, Kevin F</creatorcontrib><creatorcontrib>KOVACS, Charles J</creatorcontrib><creatorcontrib>EVANS, Mark J</creatorcontrib><creatorcontrib>DALY, Barbara M</creatorcontrib><creatorcontrib>KARLSSON, Ulf L</creatorcontrib><creatorcontrib>LEE, Tung-Kwang</creatorcontrib><creatorcontrib>ALLISON, Ron R</creatorcontrib><creatorcontrib>ARASTU, Hyder H</creatorcontrib><creatorcontrib>CARIVEAU, Mickael J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Anticancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>JOHNKE, Roberta M</au><au>EDWARDS, Judy M</au><au>O'BRIEN, Kevin F</au><au>KOVACS, Charles J</au><au>EVANS, Mark J</au><au>DALY, Barbara M</au><au>KARLSSON, Ulf L</au><au>LEE, Tung-Kwang</au><au>ALLISON, Ron R</au><au>ARASTU, Hyder H</au><au>CARIVEAU, Mickael J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Response of T Lymphocyte Populations in Prostate Cancer Patients Undergoing Radiotherapy: Influence of Neoajuvant Total Androgen Suppression</atitle><jtitle>Anticancer research</jtitle><addtitle>Anticancer Res</addtitle><date>2005-07-01</date><risdate>2005</risdate><volume>25</volume><issue>4</issue><spage>3159</spage><epage>3166</epage><pages>3159-3166</pages><issn>0250-7005</issn><eissn>1791-7530</eissn><abstract>Background: This study sought to better define the immunological impact of combining neoadjuvant total androgen suppression
(TAS) with radiotherapy (xRT) in treating prostate cancer. Materials and Methods: Subjects selected (n=37) were stage I-II
prostate cancer patients meeting the eligibility requirements for RTOG protocols 94-08 or 94-13. Flow cytometric monitoring
of circulating T helper (T h ), T suppressor/cytotoxic (T s ), natural killer (NK) and B lymphocytes was performed weekly. Results: Significant reduction of all lymphocyte subsets occurred
as a result of xRT. Comparison between treatment groups demonstrated that the B lymphocyte and NK lymphocyte radioresponse
was not influenced by TAS, but the T h and T s lymphocyte response was, with addition of TAS leading to less radiation-induced decline. Conclusion: The basis for this T
cell response is unclear, but may involve a TAS-induced reduction of testosterone's immunomodulation of T cell proliferation
and apoptosis and/or a direct, TAS-induced thymic stimulation. Our data suggest that addition of TAS to xRT appears to have
no detrimental effects on lymphocyte subsets, and, indeed, may have favorable effects on T cells.</abstract><cop>Attiki</cop><pub>International Institute of Anticancer Research</pub><pmid>16080580</pmid><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0250-7005 |
| ispartof | Anticancer research, 2005-07, Vol.25 (4), p.3159-3166 |
| issn | 0250-7005 1791-7530 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68450459 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Aged Androgen Antagonists - administration & dosage Antineoplastic Agents, Hormonal - administration & dosage Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Flutamide - administration & dosage Goserelin - administration & dosage Humans Lymphocyte Activation Male Medical sciences Middle Aged Neoadjuvant Therapy Neoplasm Staging Nephrology. Urinary tract diseases Prostatic Neoplasms - drug therapy Prostatic Neoplasms - immunology Prostatic Neoplasms - radiotherapy Prostatic Neoplasms - therapy T-Lymphocytes - drug effects T-Lymphocytes - immunology T-Lymphocytes - radiation effects Tumors Tumors of the urinary system Urinary tract. Prostate gland |
| title | Response of T Lymphocyte Populations in Prostate Cancer Patients Undergoing Radiotherapy: Influence of Neoajuvant Total Androgen Suppression |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T04%3A30%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Response%20of%20T%20Lymphocyte%20Populations%20in%20Prostate%20Cancer%20Patients%20Undergoing%20Radiotherapy:%20Influence%20of%20Neoajuvant%20Total%20Androgen%20Suppression&rft.jtitle=Anticancer%20research&rft.au=JOHNKE,%20Roberta%20M&rft.date=2005-07-01&rft.volume=25&rft.issue=4&rft.spage=3159&rft.epage=3166&rft.pages=3159-3166&rft.issn=0250-7005&rft.eissn=1791-7530&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E68450459%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68450459&rft_id=info:pmid/16080580&rfr_iscdi=true |